Skip to content

Kaletra monotherapy as effective as triple therapy for at least 18 months

Efavirenz more durable than Kaletra over two years in treament-naive patients

Access to treatment associated with declining stigma in Botswana

Vicriviroc effective in treatment-experienced patients, but malignancy questions remain unanswered

New data shed light on poor outcome in SMART study

Merck launches expanded access programme for integrase inhibitor

Oral solution of tipranavir/ritonavir shows promise for treatment-experienced kids

Researchers launch hunt for people who control HIV without drugs

Anal cancer increases in French HIV cohort, despite use of antiretroviral therapy